Feed excerpt — reported by STAT News
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →